AACR 2026: Moderna and Revolution Showcase Promising Cancer Therapy Data
At the American Association for Cancer Research (AACR) annual meeting, Moderna and Revolution Medicines presented new data on their cancer therapies. Moderna's investigational antigen therapy, mRNA-4359, combined with Keytruda, showed an 83% overall response rate in patients with advanced melanoma. Revolution Medicines shared Phase 1 data for its lung cancer drug, zoldonrasib, which demonstrated a 52% confirmed overall response rate. The meeting highlighted significant advancements in cancer treatment, with various companies showcasing their latest research and potential therapies. 
